Antex Biologics Inc has been issued five new patents, increasing the Company's total patent portfolio to 116 issued patents. The Company also has over 300 pending patent applications.
Antex's worldwide patent portfolio includes claims for composition of matter, methods of production and methods of use. The new patents expand the Company's worldwide protection of its proprietary technologies and products. Specific bacterial pathogens covered by the patents include: Haemophilus influenzae and Moraxella catarrhalis, leading causes of pediatric respiratory diseases and the subject of licensing arrangements with Aventis Pasteur and GlaxoSmithKline; and Helicobacter pylori, the leading cause of peptic ulcers and stomach cancers.
In addition to specific claims covering novel proteins and the genes encoding them, Antex's proprietary platform technologies ART (antigen receptor technology) and NST (nutriment signal transduction) are also covered by the new patents. These patents broaden the Company's intellectual property portfolio in North America, Europe and Asia.